Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines

Alice Pasini, Giulia Paganelli, Anna Tesei, Wainer Zoli, Emanuele Giordano, Daniele Calistri

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Five-year survival rate for lung cancer is limited to 10% to 15%. Therefore, the identification of novel therapeutic prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemoresistant non-small cell lung cancer cell lines. Therefore, we checked-in the control condition as well as after shortterm pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features. We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treatments and indicate specific molecular traits for their chemoresistance.

Original languageEnglish
Pages (from-to)461-468
Number of pages8
JournalTranslational Oncology
Volume5
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

gemcitabine
docetaxel
Biomarkers
Cell Line
Genes
Pharmacology
Gene Expression
Gene Expression Regulation
DNA Methylation
Tumor Suppressor Genes
Drug Resistance
Non-Small Cell Lung Carcinoma
Methylation
Cisplatin
Squamous Cell Carcinoma
Lung Neoplasms
Down-Regulation
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines. / Pasini, Alice; Paganelli, Giulia; Tesei, Anna; Zoli, Wainer; Giordano, Emanuele; Calistri, Daniele.

In: Translational Oncology, Vol. 5, No. 6, 12.2012, p. 461-468.

Research output: Contribution to journalArticle

Pasini, Alice ; Paganelli, Giulia ; Tesei, Anna ; Zoli, Wainer ; Giordano, Emanuele ; Calistri, Daniele. / Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines. In: Translational Oncology. 2012 ; Vol. 5, No. 6. pp. 461-468.
@article{c65af3343b82470d840fbd58fd00b8ec,
title = "Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines",
abstract = "Five-year survival rate for lung cancer is limited to 10{\%} to 15{\%}. Therefore, the identification of novel therapeutic prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemoresistant non-small cell lung cancer cell lines. Therefore, we checked-in the control condition as well as after shortterm pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features. We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treatments and indicate specific molecular traits for their chemoresistance.",
author = "Alice Pasini and Giulia Paganelli and Anna Tesei and Wainer Zoli and Emanuele Giordano and Daniele Calistri",
year = "2012",
month = "12",
doi = "10.1593/tlo.12256",
language = "English",
volume = "5",
pages = "461--468",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "6",

}

TY - JOUR

T1 - Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines

AU - Pasini, Alice

AU - Paganelli, Giulia

AU - Tesei, Anna

AU - Zoli, Wainer

AU - Giordano, Emanuele

AU - Calistri, Daniele

PY - 2012/12

Y1 - 2012/12

N2 - Five-year survival rate for lung cancer is limited to 10% to 15%. Therefore, the identification of novel therapeutic prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemoresistant non-small cell lung cancer cell lines. Therefore, we checked-in the control condition as well as after shortterm pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features. We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treatments and indicate specific molecular traits for their chemoresistance.

AB - Five-year survival rate for lung cancer is limited to 10% to 15%. Therefore, the identification of novel therapeutic prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemoresistant non-small cell lung cancer cell lines. Therefore, we checked-in the control condition as well as after shortterm pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features. We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treatments and indicate specific molecular traits for their chemoresistance.

UR - http://www.scopus.com/inward/record.url?scp=84871673425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871673425&partnerID=8YFLogxK

U2 - 10.1593/tlo.12256

DO - 10.1593/tlo.12256

M3 - Article

AN - SCOPUS:84871673425

VL - 5

SP - 461

EP - 468

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 6

ER -